Inhibrx Capital Expenditures from 2010 to 2024

INBX Stock  USD 14.86  0.78  5.54%   
Inhibrx Capital Expenditures yearly trend continues to be fairly stable with very little volatility. Capital Expenditures is likely to outpace its year average in 2024. During the period from 2010 to 2024, Inhibrx Capital Expenditures regression line of annual values had r-squared of  0.56 and arithmetic mean of  1,227,577. View All Fundamentals
 
Capital Expenditures  
First Reported
2018-03-31
Previous Quarter
1.2 M
Current Value
247 K
Quarterly Volatility
693.7 K
 
Covid
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 33.4 M, Minority Interest of 0.0 or Tax Provision of 2.6 K, as well as many indicators such as Price To Sales Ratio of 1 K, Dividend Yield of 0.0021 or PTB Ratio of 43.23. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
  
Check out the analysis of Inhibrx Correlation against competitors.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

Latest Inhibrx's Capital Expenditures Growth Pattern

Below is the plot of the Capital Expenditures of Inhibrx over the last few years. Capital Expenditures are funds used by Inhibrx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Inhibrx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software. It is Inhibrx's Capital Expenditures historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
Capital Expenditures10 Years Trend
Slightly volatile
   Capital Expenditures   
       Timeline  

Inhibrx Capital Expenditures Regression Statistics

Arithmetic Mean1,227,577
Geometric Mean642,680
Coefficient Of Variation123.67
Mean Deviation1,065,759
Median686,000
Standard Deviation1,518,089
Sample Variance2.3T
Range4.6M
R-Value0.75
Mean Square Error1.1T
R-Squared0.56
Significance0
Slope254,727
Total Sum of Squares32.3T

Inhibrx Capital Expenditures History

20244.8 M
20234.6 M
2022686 K
2021864 K
20201.4 M
20191.8 M
20181.4 M

About Inhibrx Financial Statements

Inhibrx investors use historical fundamental indicators, such as Inhibrx's Capital Expenditures, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Capital Expenditures4.6 M4.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.